<DOC>
	<DOCNO>NCT01341158</DOCNO>
	<brief_summary>The current clinical trial shall clarify efficacy , safety biologic effect neoadjuvant treatment natural interferon-α ( Multiferon ) patient locoregional metastasis melanoma stage IIIB/C .</brief_summary>
	<brief_title>NAM-Trial : Multiferon Malignant Melanoma</brief_title>
	<detailed_description>The study open label , multicenter phase IIa clinical trial design pilot project order establish efficacy tolerability Multiferon neoadjuvant treatment locoregional metastasis . Patients treat subsequently cohort characterize different dos ( 3 - 9 - 18 MIU ) analyze dosage dependent effect .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>1 . Histologically proven cutaneous melanoma 2 . Clinical stage IIIB IIIC ( AJCC 2010 ) 3 . ≥ 18 year age 4 . Presence least two metastasis , 10 metastasis , completely resectable 5 . Measurable disease ( least one lesion accurately measure two perpendicular diameter , dimension least 10 mm x 10 mm spiral CT 5 mm x 5 mm locoregional metastasis assess ultrasound digital photography ) 6 . ECOG performance status 0/1 7 . Patients previous adjuvant recombinant interferonα treatment dose eligible ( ) treatment stop least 1 month start treatment ( ii ) progression occur interferonα treatment . 8 . No childbearing potential negative pregnancy test within 14 day inclusion woman child bear potential Women childbearing potential must use effective method contraception ( PearlIndex &lt; 1 , e.g . oral contraceptive , hormonal contraceptive [ vaginal product , skin patch , implant injectable product ] , mechanical product intrauterine device barrier method [ diaphragm , spermicide ] ) throughout study 3 month last dose investigational product , manner risk pregnancy minimize . No men father potential men father potential must use effective method contraception avoid conception throughout study 3 month last dose investigational product , manner risk pregnancy minimize . 9 . Signed date informed consent inform consent start specific protocol procedure 1 . Mucous membrane ocular melanoma 2 . Any evidence distant metastasis ( e.g . whole body CTscan include brain scan within 4 week inclusion ) 3 . Patients severe cardiac disease ( e.g . NYHA Functional Class III IV , myocardial infarction within 6 month inclusion , ventricular tachyarrhythmia require ongoing treatment , unstable angina pectoris ) . 4 . ALAT ASAT &gt; 2 x ULN 5 . Total bilirubin &gt; 2 x ULN 6 . Creatinine &gt; 2 x ULN 7 . Evidence history depression . If condition rule , patient transfer psychiatrist consultation assessment inclusion . 8 . Patients seizure disorder require anticonvulsant therapy 9 . Any following abnormal baseline hematologic/laboratory value : Hb &lt; 10g/dl WBC &lt; 3.0x109 /l Platelets &lt; 100x109 /l 10 . Presence active autoimmune disease 11 . Concurrent systemic glucocorticoid systemic immunosuppressive therapy 12 . Unwilling unable comply requirement protocol 13 . Known infection HBV , HCV , HIV 14 . Pregnant lactate woman 15 . Unwillingness inability employ effective barrier method birth control throughout study 3 month end treatment female male patient 16 . Known suspect allergy human interferon alpha ingredient IMP . 17 . Any thyroid dysfunction responsive therapy 18 . Presence chronic hepatitis decompensated liver cirrhosis 19 . Immunosuppression patient transplantation 20 . Evidence history bleed diathesis coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Malignatn Melanoma</keyword>
</DOC>